PURPOSE Conventional and Hall Technique (HT) Preformed Metal Crowns (PMCs) are used for treatment of carious primary molars. The aim was to evaluate the clinical and radiographic success of conventional and HT PMCs in a postgraduate dental setting. METHODS A retrospective study using patients' electronic case-notes and radiographic images of carious primary molars treated with either conventional or HT PMCs was conducted to assess clinical and radiographic success/failure. A Kaplan-Meier curve was used to assess PMC survival. RESULTS 187 PMCs (110 HT and 77 conventional) in 65 children (34 females and 31 males) at 6, 12, 18 and 24&nbsp;months were assessed. At 24&nbsp;months, the success rates of conventional and HT PMCs were 97.6% and 93.5%, respectively. Two HT (perforated/abscessed) and four conventional (abscessed) PMCs failures occurred. There was no significant difference in success/failure (p?=?0.362) at 12&nbsp;months, but the HT was more successful at 24&nbsp;months (p?=?0.002) with similar survival times for both methods. CONCLUSION HT and conventionally placed PMCs, when placed in a postgraduate paediatric dentistry setting, were clinically and radiographically very successful at 6, 12, 18 and 24&nbsp;months post operatively with a slightly higher success of the HT at 24&nbsp;months.Although norovirus, rotavirus, adenovirus and Astrovirus are considered the most important viral agents transmitted by food and water, in recent years other viruses, such as Aichi virus (AiV), have emerged as responsible for gastroenteritis outbreaks associated with different foods. AiV belongs to the genus Kobuvirus of the family Picornaviridae. It is a virus with icosahedral morphology that presents a single stranded RNA genome with positive sense (8280 nucleotides) and a poly (A) chain. AiV was first detected from clinical samples and in recent years has been involved in acute gastroenteritis outbreaks from different world regions. Furthermore, several studies conducted in Japan, Germany, France, Tunisia and Spain showed a high prevalence of AiV antibodies in adults (between 80% and 99%), which is indicative of a large exposure to this virus. The aim of this review is to bring together all the discovered information about the emerging pathogen human Aichi virus (AiV), discussing the possibles routes of transmission, new detection techniques and future research. Although AiV is responsible for a low percentage of gastroenteritis outbreaks, the high seroprevalence shown by human populations indicates an evident role as an enteric agent. https://www.selleckchem.com/products/i-191.html The low percentage of AiV detection could be explained by the fact that the pathogen is more associated to subclinical infections. Further studies will be needed to clarify the real impact of AiV in human health and its importance as a causative gastroenteritis agent worldwide.In the midsession reversal task, choice of one stimulus (S1) is correct for the first half of each session and choice of the other stimulus (S2) is correct for the last half of each session. Although humans and rats develop very close to what has been called a win-stay/lose-shift response strategy, pigeons do not. Pigeons start choosing S2 before the reversal, making anticipatory errors, and they keep choosing S1 after the reversal, making perseverative errors. Research suggests that the pigeons are timing the reversal from the start of the session. However, making the reversal unpredictable does not discourage the pigeons from timing. Curiously, pigeons' accuracy improves if one decreases the value of the S2 stimulus relative to the S1 stimulus. Another form of asymmetry between S1 and S2 can be found by varying, over trials, the number of S1 or S2 stimuli. Counterintuitively, if the number of S2 stimuli varies, it results in a large increase in anticipatory errors but little increase in perseverative errors. However, if the number of S1 stimuli varies over trials, it results in a large increase in perseverative errors but no increase in anticipatory errors. These last two effects suggest that in the original midsession reversal task, the pigeons are learning to reject S2 during the first half of each session and learning to reject S1 during the last half of each session. These results suggest that reject learning may also play an important role in the learning of simple simultaneous discriminations.BACKGROUND It is unclear whether generics are as safe as brand-name drugs in cardiology. For public health surveillance purposes, we evaluated if switching from the brand-name losartan, valsartan, or candesartan impacted the occurrence of the following outcomes emergency room (ER) consultations, hospitalizations, or death. STUDY DESIGN This was a retrospective cohort study. METHODS This study was conducted in the Quebec Integrated Chronic Disease Surveillance System, including healthcare administrative data of the population of Quebec, Canada. We included brand-name users of losartan, valsartan, or candesartan aged???66&nbsp;years who had undergone???30&nbsp;days of stable treatment on the brand-name drug prior to cohort entry (substitution time-distribution matching was used to prevent immortal time bias). Outcomes up to 1&nbsp;year were compared between groups using multivariable Cox proportional hazards regression models (validity assumptions were verified). RESULTS In our cohorts (losartan, n?=15,783; valsartan, n?=16,907; candesartan, n?=26,178), mean age was 76-78&nbsp;years, 59-66% were female, 90-92% had hypertension, and 13-15% had heart failure. Validity assumptions were violated for losartan only. For patients&nbsp;switched to generic valsartan, the hazard ratio (95% confidence interval) was 1.07 (0.99-1.14) for ER consultation, 1.26 (1.14-1.39) for hospitalization, and 1.01 (0.61-1.67) for death. The corresponding rates for candesartan were 1.00 (0.95-1.05), 0.96 (0.89-1.03), and 0.57 (0.37-0.88), respectively. CONCLUSIONS We observed an increased risk of hospitalizations for patients switched to generic valsartan, and a decreased risk of death for patients switched to generic candesartan, compared with those who continued taking the brand-name drug. The differences between generic and brand-name drugs may lead to some differences in public health outcomes, but this safety signal must be further studied using other cohorts and settings.